A groundbreaking study presented at ENDO 2026, the Endocrine Society’s annual meeting in Chicago, Illinois, has revealed a surprising and potentially concerning trend: individuals experiencing significant weight loss while taking popular medications such as Ozempic, Wegovy, Mounjaro, and Zepbound have demonstrated a marked decrease in their physical activity levels. This finding challenges the common assumption that shedding excess pounds naturally translates into increased movement and exercise, prompting a closer examination of the multifaceted impact of these powerful weight-loss drugs.
The research, which analyzed data from the National Institutes of Health’s All of Us Research Program, utilized wearable fitness tracker information to objectively measure changes in physical activity among adults with obesity who initiated treatment with glucagon-like peptide-1 (GLP-1) receptor agonists. The findings suggest that while these medications are highly effective in reducing body mass, they may inadvertently contribute to a decline in users’ daily movement, highlighting the critical need for integrated strategies that prioritize exercise alongside pharmacological intervention.
The Rise of GLP-1 Receptor Agonists and Unforeseen Consequences
The landscape of obesity treatment has been dramatically reshaped in recent years by the advent and widespread adoption of GLP-1 receptor agonists. Medications like semaglutide (marketed as Ozempic for diabetes and Wegovy for weight loss) and tirzepatide (marketed as Mounjaro for diabetes and Zepbound for weight loss), along with others such as liraglutide and dulaglutide, have demonstrated remarkable efficacy in facilitating substantial weight loss for millions of individuals struggling with obesity. These drugs work by mimicking the action of the GLP-1 hormone, which plays a crucial role in regulating appetite, promoting satiety, and slowing gastric emptying. The result is often a significant reduction in calorie intake and subsequent weight loss.
However, the success of these medications has also brought to light potential side effects and broader health implications that warrant careful consideration. The study presented at ENDO 2026 sheds light on one such unforeseen consequence: a measurable decline in physical activity among users.
Study Design and Methodology: Leveraging Wearable Technology
The research team, led by Sajana Maharjan, M.D., of HSHS St. John’s Hospital in Springfield, Illinois, embarked on a comprehensive investigation to quantify the impact of GLP-1 receptor agonists on physical activity. To achieve this, they tapped into the rich dataset of the All of Us Research Program, a landmark initiative by the National Institutes of Health aimed at collecting health data from a diverse population of one million Americans. This program uniquely combines comprehensive electronic health records with data from participants’ personal wearable devices, such as Fitbits, offering an unprecedented opportunity to observe real-world behavioral changes.
The study cohort comprised 1,950 adults diagnosed with obesity who had recently started treatment with a GLP-1 medication. A critical component of the analysis involved filtering this group to include only those participants who had sufficient data from their wearable devices to allow for a robust before-and-after comparison of their activity levels. Ultimately, 753 participants met these criteria. The demographic profile of this analyzed group indicated a predominantly female population, with women constituting 78.6%, and an average age of 52.7 years. This demographic composition is largely reflective of individuals seeking and utilizing these weight-loss medications.
The researchers meticulously compared two key metrics of physical activity: daily step counts and minutes spent engaging in moderate-to-vigorous physical activity (MVPA). These objective measures provided a quantitative assessment of how participants’ movement patterns evolved following the commencement of their medication regimen.
Quantifiable Declines: The Data Unveiled
The results of the analysis painted a clear and consistent picture of reduced physical exertion. Following the initiation of GLP-1 receptor agonist therapy, participants exhibited a significant drop in both daily step counts and MVPA.
On average, daily step counts decreased from a pre-treatment baseline of 5,047 steps to 4,487 steps per day. This represents a reduction of approximately 560 steps per day, a seemingly small number but one that accumulates over time and can signify a substantial shift in overall daily movement.
Similarly, the time dedicated to moderate-to-vigorous physical activity saw a notable decline. Participants averaged 28 minutes of MVPA per day before starting the medications, a figure that fell to 22 minutes per day after treatment. This six-minute reduction in daily MVPA, while seemingly modest, is significant in the context of public health recommendations for physical activity, which often advocate for at least 150 minutes of MVPA per week.
Subgroup Analysis: Identifying Vulnerable Populations
The study further delved into potential differences in activity decline across various demographic and clinical subgroups. Intriguingly, the most pronounced decreases in physical activity were observed in men and in individuals who reported pre-existing joint or muscle pain. This finding suggests that these groups may be particularly susceptible to reduced mobility when undergoing weight loss with these medications. The presence of joint or muscle pain could exacerbate feelings of fatigue or discomfort during physical exertion, leading to a greater avoidance of activity. Similarly, men may have different physiological responses or behavioral patterns related to physical activity and weight loss compared to women.
Conversely, factors such as age, the presence of heart failure, and a history of stroke did not appear to significantly alter the observed trends in physical activity decline. This indicates that the impact on activity levels may be more directly linked to the medication itself and the physiological changes it induces, rather than being solely dictated by these pre-existing health conditions.
Crucially, the researchers found no evidence to support the notion that weight loss achieved through these medications spontaneously led to increased physical activity. This directly contradicts the intuitive assumption that becoming lighter would naturally empower individuals to move more freely and engage in exercise more readily.
Expert Commentary and Implications for Clinical Practice
The implications of these findings are significant for both patients and healthcare providers. Dr. Maharjan emphasized the importance of this revelation, stating, "While many assume that weight loss leads naturally to increased physical activity, our study suggests otherwise. The findings in our study reinforce that exercise cannot be optional for people taking these medications. People need targeted interventions that encourage physical activity alongside medication for obesity."
This statement underscores a critical shift in understanding. Historically, the focus in obesity management has often been on either diet, exercise, or medication, with the assumption that success in one area would naturally facilitate progress in others. However, this research suggests that for GLP-1 receptor agonists, a more integrated and proactive approach is essential.
The study is notable for being the first large-scale investigation to leverage wearable fitness tracker data to examine physical activity patterns among adults taking GLP-1 receptor agonists. This methodological approach offers a high degree of objectivity, moving beyond self-reported activity levels which can be prone to bias.
Broader Context and Future Directions
The findings from ENDO 2026 come at a time when GLP-1 receptor agonists are experiencing unprecedented demand. The scientific community and regulatory bodies are actively working to understand the long-term effects and optimal use of these medications. This study adds a crucial piece to that puzzle, highlighting the potential for a disconnect between weight loss and increased physical activity.
Several hypotheses could explain this phenomenon:
- Muscle Mass Loss: As the original article notes, GLP-1 receptor agonists can contribute to a loss of lean muscle mass alongside fat. Reduced muscle mass can lead to decreased strength and stamina, making physical activity feel more challenging and potentially less rewarding. Maintaining muscle mass through resistance training is vital for overall health and functional capacity, and this loss may be a significant factor in reduced activity.
- Metabolic Rate Changes: While weight loss generally leads to a lower metabolic rate, the specific impact of GLP-1 medications on metabolic rate and energy expenditure during activity warrants further investigation. It’s possible that changes in hormonal signaling might influence energy utilization in ways that are not fully understood.
- Psychological Factors: The perception of effort may also play a role. Even with weight loss, if the underlying physiological response to exercise feels more taxing due to medication effects, individuals might be less motivated to engage.
- Focus on Weight Loss as the Primary Goal: It is plausible that some individuals, focused on achieving weight loss targets with medication, may deprioritize exercise, viewing it as secondary or even unnecessary.
The implications of this research extend beyond individual patient care. Public health initiatives aimed at promoting healthy lifestyles alongside medication use will need to be re-evaluated. Healthcare providers prescribing these medications should consider incorporating structured exercise programs, potentially including resistance training, as a standard component of care. This might involve referrals to physical therapists, exercise physiologists, or specialized weight management programs that emphasize physical activity.
Further research is needed to:
- Investigate the precise mechanisms by which GLP-1 receptor agonists influence physical activity levels.
- Determine if targeted interventions, such as resistance training programs, can mitigate the observed decline in activity.
- Explore the long-term consequences of reduced physical activity in individuals using these medications.
- Examine whether different GLP-1 receptor agonists have varying impacts on activity levels.
The ENDO 2026 presentation serves as a critical reminder that while pharmacological interventions can be powerful tools in the fight against obesity, they are most effective when integrated into a holistic approach to health that includes robust strategies for promoting and maintaining physical activity. The challenge now lies in translating these research findings into actionable clinical guidance to ensure patients achieve not only weight loss but also sustainable improvements in overall health and well-being.
